Clinical Trials · NCT06607926
Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC
- Phase
- N/A
- Recruitment status
- Not Yet Recruiting
- Sponsor
- Xuanwu Hospital, Beijing
- Enrollment
- 40
- Start date
- Oct 2024
- Locations
- 1 site, China
- Primary endpoint
- Pathologic complete response rate